Nov 7, 2018
|
Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights
|
Oct 26, 2018
|
Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus
|
Oct 8, 2018
|
Ardelyx Showcases New Data from T3MPO-3 Long-Term Safety Trial of Tenapanor for IBS-C in Presidential Poster at ACG 2018 Annual Meeting
|
Oct 4, 2018
|
Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders
|
Sep 13, 2018
|
Ardelyx Submits New Drug Application for U.S. Marketing Authorization of Tenapanor for IBS-C to U.S. Food and Drug Administration
|
Aug 29, 2018
|
Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption
|
Aug 7, 2018
|
Ardelyx Reports Second Quarter 2018 Financial Results and Recent Highlights
|
Aug 1, 2018
|
Ardelyx Announces Date of Second Quarter 2018 Financial Results and Conference Call
|
May 29, 2018
|
Ardelyx to Present at the Jefferies 2018 Global Healthcare Conference
|
May 22, 2018
|
Ardelyx Announces Pricing of Public Offering of Common Stock
|